Fulltext

Short- and Long-term Immunological and Virological Outcome in HIV-Infected Infants According to the Age at Antiretroviral Treatment Initiation

Goetghebuer, Tessa ; Le Chenadec, Jerome ; Haelterman, Edwige ; Galli, Luisa ; Dollfus, Catherine ; Thorne, Claire ; Judd, Ali ; Keiser, Olivia ; Ramos, Jose Tomas ; Levy, Jack ; Warszawski, Josiane

In: Clinical Infectious Diseases, 2012, vol. 54, no. 6, p. 878-881

Zum persönliche Liste hinzufügen
    Titel
    • Short- and Long-term Immunological and Virological Outcome in HIV-Infected Infants According to the Age at Antiretroviral Treatment Initiation
    Autor
    • Goetghebuer, Tessa. Pediatric Department, CHU St Pierre, Brussels, Belgium
    • Le Chenadec, Jerome. Inserm, U822, Le Kremlin-Bicêtre, France
    • Haelterman, Edwige. Pediatric Department, CHU St Pierre, Brussels, Belgium
    • Galli, Luisa. Italian Register, Department of Paediatrics, University of Florence, Italy
    • Dollfus, Catherine. P-HP, Hôpital Trousseau, Service d'Hématologie et d'oncologie pédiatrique, Paris, France
    • Thorne, Claire. MRC Centre of Epidemiology for Child Health, Institute of Child Health, University College London
    • Judd, Ali. Collaborative HIV Paediatric Study, MRC Clinical Trials Unit, London, United Kingdom
    • Keiser, Olivia. Data Center of the Swiss HIV Cohort Study, Lausanne
    • Ramos, Jose Tomas. Pediatric Department, Hospital Universitario de Getafe, Madrid, Spain
    • Levy, Jack. Pediatric Department, CHU St Pierre, Brussels, Belgium
    • Warszawski, Josiane. Inserm, U822, Le Kremlin-Bicêtre, France
    Dokumententyp
    • Postprint
    Sprache
    • Englisch
    Veröffentlicht in
    • Clinical Infectious Diseases, 2012, vol. 54, no. 6, p. 878-881. Oxford University Press
    Andere elektronische Ausgabe
    Klassifikation
    • Gesundheit
    OAI-PMH-ID
    • oai:doc.rero.ch:298455
    Summary
    The clinical benefit of antiretroviral therapy in infants is established. In this cohort collaboration, we compare immunological and virological response to treatment started before or after 3 months of age. Early initiation provides a better short-term response, although evolution after 12 months of age is similar in both groups